TheStreet) -- STOCK COMMENTS / EPS CHANGES Brown-Forman ( BF.B) estimates decreased at UBS. BF.B estimates were lowered through 2013. Estimates adjusted after removing the contribution of Fetzer/Hopland Assets. Maintain Neutral rating and $72 price target. Cenovus Energy ( CVE) cut from Conviction Buy List at Goldman Sachs. MDR has better risk/reward at current levels. $51 price target. Discover Financial ( DFS) estimates boosted at Citigroup through 2012 citing healthy loan growth expectations and a better outlook vs. banks, Citigroup said. Maintain Hold rating and $25 price target. Humana ( HUM) estimates raised at Credit Suisse through 2013. Company is seeing lower costs and buying back more stock. Outperform rating and $100 price target. CarMax ( KMX) estimates, target lowered at Goldman. Shares of KMX now seen reaching $34, according to Goldman Sachs. Estimates also cut, given lower expected used car sales. Neutral rating. Par Pharmaceutical ( PRX) estimates lowered at UBS through 2012. Branded cost structure continues to be a drag on earnings. Maintain Buy rating and $39 price target. Qualcomm ( QCOM) estimates increased at Credit Suisse through 2012. Company should continue to see strong demand from smartphone and tablet computer makers. Outperform rating and $70 price target. Synchronoss ( SNCR) added to Conviction Buy List at Goldman Sachs. $39 price target. Company is leveraged to connected device growth. Under Armour ( UA) estimates, target raised at FBR. Shares of UA now seen reaching $75. Estimates also increased, as fundamentals are relatively better positioned than most over the near term. Market Perform rating. End of report.